Physician profile
James Vandermark
NPI 1609534791
$4,303.58
in general payments reported to CMS, 2019-2025
24 companies · $534 in 2025
The $534 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $854 · 2023: $1,638 · 2024: $1,277 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,449.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,392.24 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,011.05 | 2022-2025 | Relistor, Trulance |
| Collegium Pharmaceutical, INC. | $330.93 | 2022-2025 | Belbuca, Xtampza |
| Pfizer INC. | $214.19 | 2023-2025 | |
| Almatica Pharma LLC | $180.94 | 2023 | Gralise |
| Biohaven Pharmaceutical Holding Company Ltd. | $153.98 | 2022 | |
| Orexo US, INC. | $152.54 | 2022-2023 | Zubsolv |
| Lundbeck LLC | $149.07 | 2024 | Vyepti |
| Vertex Pharmaceuticals Incorporated | $109.73 | 2025 | |
| Scilex Pharmaceuticals INC. | $91.95 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $79.23 | 2022-2023 | Quviviq |
| Lilly USA, LLC | $76.86 | 2022-2025 | Emgality, Reyvow, Mounjaro |
| Averitas Pharma INC. | $64.72 | 2024 | Qutenza |
| Spr Therapeutics, INC | $57.77 | 2023-2024 | Sprint Pns System |
| Spinal Simplicity, LLC | $33.05 | 2024 | Ha Minuteman G3-R |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $32.08 | 2023-2025 | Tirosint, Licart, Licart |
| Tersera Therapeutics LLC | $27.66 | 2023 | Prialt |
| Indivior INC. | $24.78 | 2025 | Sublocade |
| Vertos Medical, INC. | $24.54 | 2023 | Mild Device Kit |
| Redhill Biopharma INC. | $24.38 | 2022 | |
| Stryker Corporation | $21.81 | 2025 | Augment Injectable |
| Nalu Medical, INC. | $21.41 | 2024 | Nalu Neurostimulation System |
| Seqirus USA INC | $15.54 | 2023 | Flucelvax Quadrivalent |
| Si-Bone, INC. | $13.13 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Vandermark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.